IMMP
Immutep
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Immutep reported mature overall survival data from INSIGHT-003 and provided an update on TACTI-004 in first-line NSCLCJul 13, 2026
- Eftilagimod alfa linked to significantly improved overall survival in late-stage cancer patientsMay 28, 2026
- Immutep received FDA orphan drug designation for eftilagimod alfa in soft tissue sarcomaApr 15, 2026
- Immutep reports strong progress in global Phase III TACTI-004 (KEYNOTE-F91) trial with robust enrollmentDec 16, 2025
- Immutep announces successful completion of FDA Project Optimus requirementsOct 13, 2025